Tiziana Life Sciences Partners with Renaissance Lakewood LLC to Optimize Intranasal Foralumab Formulation
New York, NY, February 21, 2025 – In an exciting development for the biotechnology industry, Tiziana Life Sciences, Ltd. (TLSA) announced a product development services agreement with Renaissance Lakewood LLC, a leading Contract Development and Manufacturing Organization (CDMO) specializing in nasal drug delivery. This collaboration marks a significant step forward in Tiziana’s efforts to optimize the current formulation of its lead development candidate, intranasal foralumab, and develop a comprehensive plan for the scale-up of this innovative therapy in a nasal device.
What is Intranasal Foralumab?
Intranasal foralumab is a fully human, anti-CD3 monoclonal antibody being developed by Tiziana for the treatment of neurodegenerative and inflammatory diseases and conditions. Foralumab works by modulating the immune system, specifically targeting CD3, a protein found on the surface of immune cells. This targeted approach offers several advantages, including a potential reduction in systemic side effects that can be associated with other immunotherapies.
The Collaboration with Renaissance Lakewood LLC
The partnership between Tiziana and Renaissance Lakewood LLC is designed to optimize the current formulation of intranasal foralumab and develop a scalable manufacturing process for this innovative therapy. CDMOs like Renaissance play a crucial role in helping biotech companies bring their therapies to market by providing critical expertise and resources during the development and manufacturing phases.
Impact on Individuals
For individuals living with neurodegenerative and inflammatory diseases or conditions, the collaboration between Tiziana and Renaissance Lakewood LLC could bring new hope for effective and targeted treatments. Intranasal foralumab’s unique mechanism of action, combined with the expertise of both companies, could lead to a more convenient and potentially less invasive treatment option. This is especially important for conditions that currently require frequent injections or other invasive treatments.
Impact on the World
The potential impact of this collaboration extends beyond the individual level, as effective treatments for neurodegenerative and inflammatory diseases can have a significant positive impact on public health and healthcare systems. According to the World Health Organization, neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases, are among the leading causes of disability and dependency among older adults worldwide. Inflammatory conditions, like multiple sclerosis and rheumatoid arthritis, also place a considerable burden on individuals and healthcare systems. The development of intranasal foralumab, with its targeted approach and potential for fewer systemic side effects, could represent a significant advancement in the treatment of these conditions.
Conclusion
The partnership between Tiziana Life Sciences and Renaissance Lakewood LLC is an exciting development for the biotechnology industry, as it brings together the innovative potential of a leading biotech company and the manufacturing expertise of a CDMO. This collaboration could lead to the optimization of intranasal foralumab’s formulation and the development of a scalable manufacturing process for this promising therapy. For individuals living with neurodegenerative and inflammatory diseases or conditions, this collaboration could bring new hope for effective and convenient treatment options. At a larger scale, the development of intranasal foralumab could have a significant positive impact on public health and healthcare systems, offering a targeted approach to addressing the burden of neurodegenerative and inflammatory diseases.
- Tiziana Life Sciences partners with Renaissance Lakewood LLC for intranasal foralumab optimization and scale-up
- Intranasal foralumab is a fully human, anti-CD3 monoclonal antibody for neurodegenerative and inflammatory diseases
- Collaboration could lead to a more convenient and potentially less invasive treatment option
- Effective treatments for neurodegenerative and inflammatory diseases could have a significant positive impact on public health and healthcare systems
